Furmonertinib before surgery for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving Furmonertinib (an oral targeted therapy) before surgery to shrink tumors in people with a specific EGFR gene mutation in their non-small cell lung cancer. The goal is to make surgery more effective and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer with an EGFR mutation (specifically exon 19 deletion or L858R).
- Your cancer must be stage II or III and considered removable by surgery.
- You must not have cancer that has spread to other parts of the body (no metastases).
- You must be in good enough health for surgery, with normal organ function (like liver, kidneys, and blood counts).
- You must be 18 years or older, and if you can become pregnant or father a child, you must use reliable birth control during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
This trial tests whether taking furmonertinib alone, or furmonertinib plus bevacizumab, before surgery can improve outcomes for people with EGFR-mutated lung adenocarcinoma that has not spread to distant organs. It may help shrink the tumor and make surgery more effective.
This trial tests whether combining an EGFR-targeting drug (furmonertinib) with either ablation or radiation therapy can help patients with early-stage lung cancer who cannot have surgery or choose not to. The goal is to see if this combination approach works better than treatment alone.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This trial tests a higher dose of a targeted therapy called furmonertinib for people with advanced lung cancer that has stopped responding to a previous drug called osimertinib. It may help if you have a certain EGFR mutation and your cancer has grown outside the brain.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.